Amivantamab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Amivantamab (ncit:C124993)
RxNorm: amivantamab (rxcui:2549199, omop:1536935)
SNOMED: Amivantamab (sctid:1162751008, omop:37160574)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| EMA (1) FDA (1) | EGFR Exon 20 (Insertion) | Non-Small Cell Lung Cancer | Amivantamab | |
| EMA (3) FDA (2) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| EMA (3) FDA (2) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Lazertinib | |
| EMA (1) FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed | |
| EMA (1) FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Amivantamab, Carboplatin, Pemetrexed |